Targeted survival improvements in clinical trials: Are you an absolutist or relativist?

Cancer

Volumn 121, Issue 3, 2015, Pages 335-338

  Paul, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ERROR; CLINICAL TRIAL (TOPIC); DATA PROCESSING; EDITORIAL; FOLLOW UP; HAZARD RATIO; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RESTRICTED MEAN SURVIVAL TIME; SAMPLE SIZE; STATISTICAL ANALYSIS; STUDY DESIGN; SURVIVAL TIME; FEMALE; HUMAN; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921523837     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29031     Document Type: Editorial

References (12)

1. Castonguay V, Wilson M, Diaz-Padilla I, Wang L, Oza A. Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. Cancer. 2015;121:413-422.
2. Cook JA, Hislop J, Adewuyi TE, et al. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. Health Technol Assess. 2014;18:v-vi, 1-175.
3. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277-1280.
4. Gan HK, You B, Pond GR, Chen EX. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst. 2012;104:590-598.
5. Perren T, Swart A, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
6. Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359-364.
7. Thoren FB, Anderson H, Strannegard O. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunol Immunother. 2013;62:1547-1551.
8. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380-2385.
9. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.
10. Todd S, Valdes-Marquez E, West J. A practical comparison of blinded methods for sample size reviews in survival data clinical trials. Pharm Stat. 2012;11:141-148.
11. Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol. 2012;30:1750-1754.
12. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30:1030-1033.